[1] Hassan ME, Highsmith EW. Phage display technology:clinical applications and recent innovations[J]. Clin Biochem, 2002, 35(6):425-445.
[2] Mori T. Cancer-specificligandsidentified from screening of peptidedisplay libraries[J]. Curr Pharm Des, 2004, 10(19):2335-2343.
[3] Zitzmann S, Mier W, Schad A, et al. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy[J]. Clin Cancer Res, 2005, 11(1):139-146.
[4] Weller EG, Wong MK, Modzelewsk RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast mierobubbles targeted via the tumor-binding peptide arginine-arginine-leucine[J]. Cancer Res,2005, 65(2):533-539.
[5] Valadon P, Garnett JD, Testa JE, et al. Screening phage display libraries for organ-specific vascular immunotargeting in vivo[J]. Proc Natl Acad Sci USA, 2006, 103(2):407-412.
[6] Hoffman JA, Giraudo E, SinghM, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma[J]. Cancer Cell, 2003, 4(5):383-391.
[7] Joyce JA, Laakkonen P, Bernasconi M, et al. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis[J]. Cancer Cell, 2003, 4(5):393-403.
[8] Barth S, Huhn M, Matthey B, et al. Ki-4(scFv)-ETA, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice[J]. Blood, 2000, 95(12):3909-3914.
[9] Adams GP, Shaller CC, Dadachova E, et al. A single treatment of Yttrium-90-1abeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice[J]. Cancer Res, 2004, 64(17):6200-6206.
[10] Asano R, Sone Y, Makabe K, et al. Humanization of the bispeeifie epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent[J]. Clin Cancer Res, 2006, 12(13):4036-4042.
[11] Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors[J]. Nat Rev Cancer, 2002, 2(10):727-739.
[12] Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)[J]. Nat Biotechnol, 2000, 18(11):1185-1190.
[13] Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor eells[J]. Proc Natl Acad Sci USA, 2004, 101(25):9381-9386.
[14] Larocca D, Baird A. Receptor-mediated gene transfer by phagedisplay vectors:applications in functional genomics and gene therapy[J]. Drug Discov Today, 2001, 6(15):793-801.
[15] Krag DN, Fulle SP, Oligino L, et al. Phage-displayed random peptide libraries in mice:toxicity after serial panning[J]. Cancer Chemother Pharmacol, 2002, 50(4):325-332.
[16] Arap W, Kdonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display[J]. Nat Med, 2002, 8(2):121-127.
[17] Krag DN, Shukla GS, Shen GP, et al. Selection of tumor-binding ligands in cancer patients with phage display libraries[J]. Cancer Res, 2006, 66(15):7724-7733.